Plenolin 

Plenolin is an anticancer agent. Plenolin exhibits inhibitory activity against human epidermoid carcinoma cells. Plenolin shows in vivo antitumor activity against ascites carcinosarcoma and lymphocytic leukemia in rodent models. Plenolin can be used for research related to ascites tumors and leukemia^[1].

Plenolin (Compound 3) exhibits a cytotoxic ED₅₀ of 0.814 μg/mL against H.Ep.-2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Plenolin (33.3 mg/kg; i.p.; once daily for 7 days) exerts 100.0% inhibitory effect on the growth of Ehrlich ascites carcinoma in male CF₁ mice, completely suppresses ascites accumulation, and the survival rate of treated mice reaches 100% on day 7^[1].
For male rats bearing Walker 256 ascitic carcinosarcoma, the T/C value of mean survival days is 207 when treated with Plenolin at 2.5 mg/kg via i.p. administration^[1].
Plenolin (25 mg/kg; i.p.) results in a T/C value of 134 for mean survival days in male DBA/2 mice inoculated with P388 leukemia^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

264.32

C₁₅H₂₀O₄

34257-95-9

C[C@@]12[C@]([C@H](C)C[C@@]3([C@]([C@@H]1O)([C@H](C)C(=O)O3)[H])[H])(C=CC2=O)[H]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hall IH, et al. Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones. J Med Chem. 1977;20(3):333-337.  [Content Brief]